enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.40.

ENGN has been the topic of a number of recent research reports. Guggenheim initiated coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price objective on the stock. Morgan Stanley initiated coverage on enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective on the stock. SVB Leerink initiated coverage on enGene in a research report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price objective on the stock. Leerink Partnrs restated an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Finally, UBS Group initiated coverage on enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 price objective on the stock.

enGene Price Performance

Shares of enGene stock opened at $15.50 on Monday. The company’s 50 day moving average price is $16.20. enGene has a 12 month low of $6.69 and a 12 month high of $43.00.

Insider Transactions at enGene

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the firm’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares in the company, valued at approximately $45,542,295. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BVF Inc. IL purchased a new position in enGene during the 4th quarter worth $20,777,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter valued at $10,441,000. Vivo Capital LLC bought a new stake in enGene during the 4th quarter valued at $6,264,000. Finally, Fcpm Iii Services B.V. bought a new stake in enGene during the 4th quarter valued at $80,097,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.